Environmental Risk Factors in Psoriasis: The Point of View of the Nutritionist by Barrea, Luigi et al.




Environmental Risk Factors in Psoriasis: The Point of
View of the Nutritionist
Luigi Barrea 1,*, Francesca Nappi 1, Carolina Di Somma 2, Maria Cristina Savanelli 1,
Andrea Falco 1, Anna Balato 3, Nicola Balato 3 and Silvia Savastano 4
1 I.O.S. & COLEMAN Srl, 80011 Naples, Italy; dott.ssa.nappi@gmail.com (F.N.);
cristysav@hotmail.com (M.C.S.); falco.and@gmail.com (A.F.)
2 IRCCS SDN, Napoli Via Gianturco 113, 80143 Naples, Italy; cdisomma@unina.it
3 Dipartimento di Medicina Clinica e Chirurgia, Unit of Dermatology, Federico II University
Medical School of Naples, Via Sergio Pansini 5, 80131 Naples, Italy; anna.balato@unina.it (A.B.);
nicola.balato@unina.it (N.B.)
4 Dipartimento di Medicina Clinica e Chirurgia, Unit of Endocrinology, Federico II University
Medical School of Naples, Via Sergio Pansini 5, 80131 Naples, Italy; sisavast@unina.it
* Correspondence: luigi.barrea@unina.it; Tel.: +39-081-746-3779
Academic Editor: Peter Clifton
Received: 28 May 2016; Accepted: 19 July 2016; Published: 22 July 2016
Abstract: Psoriasis is a common, chronic, immune-mediated skin disease with systemic
pro-inflammatory activation, where both environmental and genetic factors contribute to its
pathogenesis. Among the risk factors for psoriasis, evidence is accumulating that nutrition plays
a major role, per se, in psoriasis pathogenesis. In particular, body weight, nutrition, and diet may
exacerbate the clinical manifestations, or even trigger the disease. Understanding the epidemiological
relationship between obesity and psoriasis is also important for delineating the risk profile for the
obesity-related comorbidities commonly found among psoriatic patients. Moreover, obesity can
affect both drug’s pharmacokinetics and pharmacodynamics. Additionally, the overall beneficial
effects on the obesity-associated comorbidities, clinical recommendations to reduce weight and to
adopt a healthy lifestyle could improve the psoriasis severity, particularly in those patients with
moderate to severe disease, thus exerting additional therapeutic effects in the conventional treatment
in obese patients with psoriasis. Education regarding modifiable environmental factors is essential
in the treatment of this disease and represents one of the primary interventions that can affect the
prognosis of patients with psoriasis. The goal is to make psoriatic patients and health care providers
aware of beneficial dietary interventions. The aim of this review is to assess the relevance of the
environmental factors as modifiable risk factors in psoriasis pathogenesis, with particular regard
to the involvement of obesity and nutrition in the management of psoriasis, providing also specific
nutrition recommendations.
Keywords: environmental risk factors; nutritionist; obesity; body composition; bioelectrical
impedance analysis; phase angle; lifestyle; nutrition; Mediterranean diet
1. Introduction
Psoriasis is a common, chronic, immune-mediated skin disease with systemic pro-inflammatory
activation, where both environmental and genetic factors contribute to its pathogenesis [1]. Psoriasis
usually occurs in the second-to-fourth decade of life, and males and females are equally affected [2].
The worldwide prevalence of psoriasis is around 2%–4% [3], but studies in developed countries
have reported higher prevalence rates of on average about 4.6% [4]. Nearly two thirds of patients with
psoriasis have a mild form of the disease, with less than 3% of the skin surface of the body affected,
but others have more extensive involvement of the skin. Of interest, psoriasis is associated with an
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increased metabolic risk in a manner that varies with the severity of psoriasis [5,6]. According to recent
literature data, psoriatic patients show a greater prevalence of obesity [7] and metabolic syndrome [8],
which confers a higher cardiovascular risk [9]. In this, inflammation could be the common link between
psoriasis and obesity [7]. In addition, there is growing recognition that psoriasis has a negative impact
on quality of life, reduces productivity at work, increases physical disability, and impairs social
functioning [10]. Thus, the treatment of environmental modifiable risk factors (i.e., diet, nutrition, or
physical activity) and modulation of the systemic inflammatory response are important therapeutic
goals in the integrated management of psoriatic patients [11].
In most of the studies evaluating the metabolic risk in psoriatic patients, body mass index (BMI)
has been employed as a measure of obesity. BMI is not, however, a measurement of body adiposity
as it does not provide a good indication of the ectopic location of fat deposition, mainly visceral
adiposity, which has been found to be more closely related to cardiovascular health risk than total
fat mass [12,13]. Bioelectrical impedance analysis (BIA) is relatively simple, quick, and non-invasive,
which gives reliable measurements of body composition with minimal intra- and inter-observer
variability [14]. The results are available immediately and reproducible, with <1% error on repeated
measurements [15]. In this contest, only few studies have investigated the association between psoriasis
and body composition [16], or have based the specific nutritional assessment on body composition.
Recent clinical evidence supports that nutritional assessment may provide a viable support in psoriatic
patients to improve either the disease severity and the obesity-related comorbidities [6,17].
Thus, the aim of this review is to highlight the possible relationship between psoriasis and body
weight, going beyond BMI, focusing on the impact of obesity on the medical treatment of psoriasis,
and the role of diet and nutrition in psoriasis.
2. Obesity and Psoriasis
2.1. Role of Low-Grade Inflammation
Obesity is an important risk factor for psoriasis [7]. The relationship between the two conditions
is probably bidirectional, with obesity predisposing to psoriasis and psoriasis favouring obesity [18].
Obesity is considered a chronic, low-grade inflammatory condition and the adipose tissue is an active
endocrine organ that has a key role in lipid and glucose metabolism, inflammation and coagulation, and
insulin-mediated processes. Macrophages are the key immune cell type that perpetuates inflammation
within adipose tissue. Activated macrophages in adipose tissue stimulate adipocytes to secrete
inflammatory mediators that establish and maintain the low-grade inflammatory state in obesity.
Adipose tissue, especially visceral adipose tissue, then secretes bioactive products collectively known
as adipocytokines or adipokines [19].
Several lines of basic and translational researches suggest that adipocytes and inflammatory-type
macrophages are involved in the link between psoriasis and obesity [18]. The co-existence of psoriasis
and obesity is at least in part attributed to the function of adipokines and their downstream effects.
The role of the various adipokines in psoriasis is an area of active investigation [18]. For example,
leptin is an adipokine that serves as an afferent signal of the nutritional and fat mass status to the
hypothalamus and thereby regulates appetite and body weight [20]. In addition to the regulation
of food intake, leptin plays important roles in the chronic pro-inflammatory state associated with
visceral obesity, metabolic syndrome, and their complications, such as atherosclerosis [21], possibly by
impairment of insulin signalling at the insulin receptor substrate-1 phosphorylation [22]. Studies in
psoriasis have shown that leptin levels are elevated in psoriatic patients compared with healthy
controls, and psoriasis is an independent risk factor for hyperleptinemia [23]. Contrariwise, plasma
levels of adiponectin, a cytokine with insulin-sensitizing and anti-inflammatory, are decreased in
psoriasis patients compared with healthy controls and inversely correlated with psoriasis severity
and tumour necrosis factor (TNF)-α levels, the cytokine that has been proposed as a link between
obesity and insulin resistance [24]. On the one hand, TNF-α is overexpressed in adipose tissue from
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obese animals and humans, while on the other hand its excessive production is evidenced in the skin
or joints in psoriasis and psoriatic arthritis leading to the rapid growth of skin cells and/or damage
to joint tissue. Consequently, TNF-α may also contribute to the extent of psoriatic lesions in obese
patients. Blocking the TNF-α production helps stop the inflammatory cycle of psoriatic disease, but it
does not improve insulin sensitivity in obese patients with type 2 diabetes [25]. Further evidence of a
link between obesity, inflammation, and cardiovascular diseases in patients with psoriasis is provided
by several studies reporting a positive correlation between obesity, the clinical severity of disease,
evaluated by the Psoriasis Area and Severity Index (PASI) [26], and increased of C-reactive protein
(CRP) levels [27], an acute phase protein representing the most sensitive markers of inflammation and
an independent risk for cardiovascular disease.
Although obesity likely predates or co-exists with psoriasis, a slightly increased risk for developing
obesity has been reported in patients with existing psoriasis compared with controls [7]. Sedentary
lifestyle and psoriasis can also be closely connected [28]. Indeed, according to the 2003–2004 and
2005–2006 NHANES dermatology questionnaires [29], psoriatic patients are reluctant to engage in
physical activities where their skin disease may be visible to others. Thus, in addition to genetic and
immune-mediated mechanisms, behavioural factors may have an additional role in explaining the
association between obesity and psoriasis.
As discussed later, BMI greater than 30 kg/m2 may potentially play a role in patients’ abilities
to achieve the full therapeutic effect of psoriasis therapy. This could be for two possible reasons:
it may be a consequence of decreased drug distribution into the body, as a result of increased body
mass, or it may be a consequence of increased pro-inflammatory cytokine release, as a result of the
adipocyte dysfunction [7,18,19]. Given the potential correlation between elevated BMI and increasing
psoriasis severity, weight loss has been considered as a potential adjunct to other psoriasis therapies.
Romero-Talamás and colleagues [30] reported that almost 40% of 33 morbidly obese individuals with
psoriasis on active medical treatment undergoing bariatric surgery showed significant improvement
of clinical severity of psoriasis positively related to the degree of postoperative weight loss.
2.2. Obesity: Going beyond the BMI
A diagnosis of obesity is established by determining the patient’s BMI using the formula weight
in kilograms divided by the square of the height in meters. The current World Health Organization
weight classification for BMI in adults is as follows: a BMI of between 18.5 kg/m2 and 24.9 kg/m2 is
normal, 25.0 kg/m2 to 29.9 kg/m2 is overweight, and a BMI greater than 30.0 kg/m2 is diagnostic of
obesity [31].
Several studies have been conducted to explore the association between obesity and psoriasis
using BMI [32,33]. However, the epidemiological evidence currently available is insufficient to
establish which comes first, obesity or psoriasis [18]. In particular, there was a two-fold increased
risk for psoriasis development in the setting of obesity as compared with normal weight subjects [34].
In addition, for each unit increment increase in BMI was reported a 9% higher risk for psoriasis onset
and a 7% higher risk for increased of PASI score [35]. BMI is a commonly used surrogate for adiposity
that is inexpensive and easily measured. Nevertheless, BMI evaluates excess weight rather than excess
fat [36], as it does not measure body fat directly, and poorly distinguishes between fat mass and lean
or bone mass [37]. The National Heart, Lung and Blood Institute Clinical Guidelines recognizes this
limitation of BMI [38]; thus, waist circumference (WC) is recommended as an additional surrogate
measure of fat distribution, due to its high correlation with visceral fat [39], the main source of
inflammatory cytokines in obesity [40]. While in most of the studies evaluating the association between
obesity and psoriasis, BMI has been employed as a measure of obesity, a number of studies have
evidenced a strict association between WC and psoriasis [41], being the production of inflammatory
cytokines in visceral obesity the link involved in the complex mechanisms leading to the exacerbation
of psoriasis [16]. Only few studies have assessed body composition in psoriatic patients by BIA [42–44].
Significant relationships have been evidenced between body composition and the occurrence of
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psoriasis [45], the severity of the disease [46], or the response to treatment with anti-TNF-α agents [47].
However, BIA is not a direct method for assessment of body composition and its accuracy as an
indicator of body composition could be hampered by an altered distribution of extra- and intra-cellular
water [48].
Differently from the other parameters obtained by BIA, the phase angle (PhA), a direct BIA
measure, is a rapid, easy, and bloodless tool in clinical setting and is a general indicator of cell
membrane integrity. The PhA represents either the reactance of tissues associated with cellularity,
cell size and integrity of the cell membrane, and the resistance of tissues, which is dependent on lean
tissue mass and tissue hydration [48]. It is well established that a decrease in PhA is consistent with
cell death, reflecting a breakdown of cell membranes. Consequently, the loss of the cell membrane
integrity results in a decrease in intracellular water, an increased spacing among affected cells, with
the expansion of the interstitial fluid space. On the other hand, larger PhAs reflect higher quantities of
intact cell membranes and lean body mass [49].
Very recently, we have reported a novel association between PhA, and psoriasis. In particular, our
data well demonstrated that PhA was smaller in psoriatic patients than in healthy subjects, and that
this difference is independent of gender. In addition, we found significant correlations between PhA
with the clinical severity of psoriasis, expressed by PASI score, CRP levels, and the quality of life in
these patients, independently of BMI. Based on ROC curve analysis, PhAs ď4.8˝ and ď4.9˝ identified
psoriatic patients who have the highest clinical severity and the lowest quality of life, respectively [50].
2.3. Impact of Obesity on the Treatment of Psoriasis
The cornerstones of treatment of the obesity are the management of weight and ensuring
appropriate levels of physical activity, as demonstrated by studies showing that dietary modification
and enhanced physical activity may delay or prevent the transition from impaired glucose tolerance
to type-2 diabetes [51]. Obesity also has important implications in the treatment of psoriasis. Indeed,
obesity has been associated with a decreased response to systemic and biologic therapies [18]. This may
be due to pharmacokinetic factors and affect more particularly the drugs administered in fixed doses
than those in which dose is adjusted to the patient’s weight. On the one hand, obese patients with
psoriasis are at greater risk of adverse effects with conventional systemic drugs. In particular, those
biological drugs in which dose is not weight-adjusted, such as etanercept and adalimumab, may be
less effective, where other biological drugs, such as infliximab and ustekinumab, for which dose is
weight-adjusted, the increased cost of treatment should also be considered [18]. Weight loss will
decrease the risk of drug toxicity and enhance effectiveness and tolerance, particularly in the case of
drugs administered at fixed doses. In addition to the potential decrease in the effectiveness of treatment
and the greater risk of adverse effects, obesity also substantially increases the cost of treatment with
drugs prescribed in weight-adjusted doses. Bardazzi and colleagues reported that in 33 moderate to
severe psoriasis patients treated with biological drugs, the only seven patients who decreased their
weight achieved the highest improvement in mean PASI score at the end of the study, even when
not responding at the first follow up [52]. More recently, evidence has been provided that in obese
patients with psoriasis on biologics undergoing a 8 weeks dietary programme with a low calorie diet
(ď1000 kcal per day), the body weight reduction was associated with an increase in the efficacy of the
drug [53]. Therefore, the lifestyle interventions, particularly weight reduction, may even enhance the
efficacy of psoriasis treatment, as demonstrated in a recent randomized trial and by case reports of
dramatic improvement of psoriasis after bariatric surgery in morbidly obese psoriatic patients [18].
A further aim of the management of obese patients with psoriasis should be to achieve also a reduction
in the obesity-related inflammation. On the other hand, obesity is associated with conditions such as
metabolic syndrome and hepatic steatosis, which can increase the risk of adverse effects to conventional
systemic treatment for psoriasis [6].
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3. Nutrition and Diet in Psoriasis
Among the risk factors for psoriasis, evidence is accumulating that nutrition plays a major
role, per se, either in the pathogenesis of psoriasis or in affecting drug pharmacokinetics and
pharmacodynamics [18,54,55]. However, in the vast majority of the results it is difficult to discriminate
between the effect of weight loss and dieting per se.
Severe psoriasis has been associated with nutritional deficiencies because of an accelerated loss of
nutrients from the hyperproliferation and desquamation of the epidermal layer of skin [56]. Indeed, in
severe cases the psoriasis can result in an insufficient nutritional status which may even be promoted by
nutrient-drug interactions. Limited data exist regarding the role of specific diet regimens in psoriasis,
mainly with the aim to reduce cardiac risk factors and obesity-related comorbidities. Previous studies
or single case reports reported the positive effects of low-energy diets and vegetarian diets [54],
formula diet weight loss programmes [57], gluten-free diet [58], very low-calorie carbohydrate-free
(ketogenic) [59]. Fasting periods or vegetarian diets [54,55], and diets rich in omega-3 polyunsaturated
fatty acids (ω-3 PUFA) from fish oil [60] have been associated with improvement of psoriasis in clinical
trials. In this, the reduced amounts of arachidonic acid and the increased eicosapentaenoic acid intake
might result in an anti-inflammatory environment [61]. Some psoriatic patients are gluten-sensitive
and may benefit from a gluten-free diet [58,59,62]. It is believed that some vitamins (A, E and C),
and oligoelements (iron, copper, manganese, zinc, and selenium) have anti-oxidants ability, which
decrease oxidative stress and the production of reactive oxygen species [17,63]. In addition, along
with improving glucose, insulin and lipid control, food fibres also play an important role in systemic
inflammation, by decreasing the oxidative stress produced by the elevated intake of high-simple
carbohydrate foods. Finally, due to its role in proliferation and maturation of keratinocytes, vitamin D
has become an important therapeutic option in the treatment of psoriasis [64].
Monounsaturated fatty acids (MUFA) are considered a healthy dietary fat, as opposed to saturated
fatty acid. The most frequently consumed MUFA rich dietary oils is extra virgin olive oil (EVOO).
Traditionally, the beneficial effects of EVOO have been attributed to its high MUFA content (oleic
acid), as it protects lipoproteins and cellular membranes from oxidative damage [65]. Very recently, we
have demonstrated that psoriatic patients, compared to the control group, have a higher consumption
of simple carbohydrates, total fat andω-6/ω-3 PUFA ratio, with a lower intake of protein, complex
carbohydrates, MUFA,ω-3 PUFA, and fibres [66]. In particular, in this study we found that the lowest
intake of MUFA was associated with the highest clinical severity of psoriasis. The association between
low MUFA intake and progression of psoriasis is in line with the same observation reported in other
chronic inflammatory diseases [67,68]. Additionally, the relationship of psoriasis with either individual
nutrients or individual food groups, it should be kept in mind that diet is a complex combination
of foods from various groups and nutrients, and some nutrients are highly correlated. Thus, it is
challenging to separate the effect of a single nutrient or food group from that of others in free-living
populations [69].
4. Association between the Severity of the Disease and Adherence to the Mediterranean Diet
Recent evidence has confirmed that adherence to a healthy diet over time reduces the risk
of long-term inflammation [70–72]. In particular, Barbaresko et al. [72] reported that fruit and
vegetable-based healthy dietary patterns were associated with lower biomarkers of inflammation,
such as CRP levels.
The traditional Mediterranean diet (MD) is a healthy diet characterised with the abundance of
vegetable foods and cereals, such as green and yellow vegetables, salads, legumes, bread, pasta, fruits
and nuts [73]. MD is a highly palatable and favourable diet and may lead to a higher adherence among
dieters in the long term. EVOO is the main source of fat and the intake of fish, poultry, dairy products,
and eggs is moderate. In addition, different amounts of wine are usually consumed in moderation
with meals. Animal fats used in butter, cream, and lard are not included in this diet. The MD is
considered a healthy eating pattern, associated with reduced risk for metabolic [74], cardiovascular [75],
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neoplastic [76], and chronic inflammatory diseases [77]. One of the most accredited hypothesis of
this association is that the high content of different beneficial compounds, such as antioxidants and
polyphenols, largely present in Mediterranean foods, such as plant foods, fruits and red wine, have
anti-inflammatory and antioxidant properties [60,61,78]. In particular, the MUFA intake have health
benefits on the reduction of a coronary heart disease risk, the prevention of several types of cancers,
the modification of the immune and inflammatory responses and the reduction of the osteoporosis
risk [64,65,79]. The association between MD and the lowered incidence of chronic inflammatory
diseases is well-supported by intervention studies with the MD [80].
Although the exact mechanisms of these protective properties are not fully unravelled,
β-carotenoids, folic acid, and fibres, characteristic for this diet, are known to play a pivotal role
in the prevention of oxidative stress [17]. Different studies evidenced that single foods typical
of MD, such as fruits, vegetables, and whole grains, are associated with lower concentrations of
CRP levels [81,82]. In contrast, following intake of energy-dense, nutrient-poor, processed foods,
meal-induced inflammation has been evidenced by immediate increases in CRP levels [83]. In this,
we have recently reported that, among the basic components of the MD, the intake of EVOO and fish
have an independent predictive value for clinical severity and CRP levels in psoriatic patients [46].
In addition, other nutrient and non-nutrient components of MD foods, such as β-carotene, zinc,
selenium, vitamin C, and vitamin E, have been shown to be associated with lower levels of markers of
inflammation [84]. In particular, the flavonoid compounds present in vegetables, the most important
sources of phenolic, are considered to mainly provide the antioxidant effects [58]. In addition,
vegetables are also an important source of phytosterols that reduce cholesterol serum levels and,
subsequently, the cardiovascular risk [63]. Protective actions against oxidative mechanisms are also
exerted by fruits, other basic element of the MD, due to the high amount of fibres, vitamins, minerals,
flavonoids, and terpenes. Even condiments commonly used in the MD to increase the palatability,
including garlic, onions, cappers, herbs, contain large quantities of flavonoids or allicin, the latter
known to have cardiovascular and neurocognitive benefits [62,75]. Theω-3 PUFA, (eicosapentaenoic
and docosahexaenoic acids), mainly found in fish and nuts, contribute to provide the protection
of several chronic diseases [64]. EVOO, besides the high levels of MUFA, is a source of several
phytochemicals (i.e., polyphenolic compounds, squalene and α-tocopherol). Finally, the dairy products
of the MD, such as yoghurt, are better tolerated by the lactose-intolerant subjects and might induce
favourable changes in the gut microflora, with positive effect also on the risk of colon cancer [74].
In summary, rich diversity of foods of the traditional MD encompasses these dietary characteristics
resulting in a unique compendium of nutrients that contributes to its protective effects against psoriasis
and other chronic inflammatory diseases.
Recent data provided by our group demonstrated that there was a significant association the
adherence to the MD with the severity of psoriasis, and CRP levels. In particular, the results of
our study showed that a higher percentage of psoriatic patients have a low adherence to the MD
compared with the age- sex- and BMI-matched control group, with a strict relationship between
a higher consumption of EVOO and a lower psoriasis severity. This association suggests that the
beneficial effects of nutritional interventions promoting the Mediterranean food pattern could be
extended to psoriatic patients.
5. The Point of View of the Nutritionist
The nutritional assessment, based on body composition, and lifestyle modifications should be
an integral component of management of the psoriatic patients. These “easy” concepts might be of
strategic relevance in terms of clinical efficacy and cost-effectiveness of the newer biological drugs.
A diet regimen rich in MUFA and ω-3 PUFA, fruits, vegetables, fibre, with the reduced intake of
saturated fats, simple carbohydrates, and sweetened drinks, should be recommended to the psoriatic
patients. The role of nutritional supplements has been extensively evaluated in a recent review [17].
Nutrition and dietetic recommendations might be summarized as follows:
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Foods to include:
‚ Cold water fish, such as salmon, herring, mackerel, and trout, due to their content inω-3 PUFA
and vitamin D. It is recommended especially to prefer wild fish (not farmed), to also prevent the
ingestion of harmful chemicals and toxic additives. Flaxseed and evening primrose oil might be
also used as additional dietary sources.
‚ Whole grains, legumes, vegetables, and fruits as rich source dietary fibre, trace elements, including
zinc and selenium, and vitamins. In particular, orange and yellow vegetables contain vitamin
A, pumpkin seeds that provide zinc, often deficient in patients with psoriasis [85], and brewer’s
yeast, as its content in vitamin B12 has been reported to be effective in improving the psoriatic
skin lesion [17].
‚ EVOO, as main source of dietary fat.
‚ Foods to avoid: Alcohol, gluten, given the higher prevalence of celiac disease among psoriatic
patients, red meat, and dairy products, due to their high content in saturated fat, peppers; the
association between caffeine, including coffee, tea black, mate, dark chocolate, remains still to be
ascertained [86].
‚ In addition to fish oil rich in ω-3 PUFA, other dietary supplements with vitamin D and B12 or
selenium still need further evidence on their clinical effectiveness in large population samples.
The goal of these recommendations is to make psoriatic patients and health care providers aware
of beneficial dietary interventions. Achieving dietary-related goals includes an integrated effort
of a trained team that involves the psoriatic patients in the decision-making process. It should be
recommended that, among the team members a leading role in providing nutrition care should be
given to skilled nutritionists, with all team members knowledgeable about the dietary interventions
and supporting nutrition and dietetic recommendations.
6. Conclusions
Significant associations between environmental risk factors and psoriasis have been systematically
observed. Understanding the bidirectional relationships between obesity and psoriasis is also
important for delineating the risk profile for comorbidities that may result from obesity. Weight loss
might be of strategic relevance in terms of the clinical efficacy and the cost-effectiveness of the newer
biological drugs for treatment of psoriasis. In addition to weight loss, to adopt a healthy lifestyle
could have per se beneficial effects on psoriasis severity, particularly in those with moderate to severe
disease, and exert additional therapeutic effects in the conventional treatment in obese patients with
psoriasis. Education regarding modifiable environmental factors (diet, nutrition, appropriate weight,
and physical activity) is essential in the treatment of this disease and represents one of the primary
interventions that can affect the prognosis of patients with psoriasis. Achieving dietary-related goals
includes an integrated effort of a trained team, where skilled nutritionists should play a central role
and the psoriatic patients should actively participate in the decision-making process. On the basis of
its components, the MD presents health benefits and can prevent obesity, diabetes, and cardiovascular
conditions. The beneficial effects of nutritional interventions promoting the Mediterranean food
pattern could be extended to psoriatic patients. Future well-designed dietary intervention trials on
larger population samples are needed to define specific dietary guidelines for psoriasis.
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